שימוש בelectroretinogram כדי להעריך את התפקוד ברשתית מכרסמים וההשפעות המגנות של האיבר המרוחק איסכמי אכשור קד

Executive Industry Relevance

Electroretinogram (ERG) assessment in rodent models enables quantitative evaluation of retinal function and neuroprotective interventions, supporting early-stage target validation in ophthalmic drug discovery. The protocol's ability to distinguish rod and cone responses and measure functional outcomes after remote limb ischemic preconditioning provides predictive confidence for mechanistic de-risking and translational continuity. This approach is directly relevant for portfolio triage and prioritization of neuroprotective strategies in preclinical pipelines.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of neuroprotective hypotheses in retinal injury models.
• Supports functional target validation by quantifying photoreceptor and inner retinal responses.
• Facilitates mechanistic de-risking by isolating rod and cone pathway contributions.
• Provides predictive confidence for advancing neuroprotective candidates.

Screening & Assay Development

• Establishes validated, reproducible ERG protocols for functional screening of interventions.
• Delivers quantitative, standardized readouts (A wave, B wave amplitudes) for compound evaluation.
• Enables scalability and platform reuse across pharmacological and genetic models of retinal injury.
• Supports screening of animals with visual defects for preclinical candidate selection.

Translational & Preclinical Research

• Aligns functional ERG endpoints with disease-relevant retinal injury models.
• Enables continuity from discovery through preclinical validation of neuroprotective strategies.
• Supports risk-adjusted advancement decisions based on quantitative functional outcomes.
• Facilitates translational biomarker development for retinal neuroprotection.

Pipeline & Workflow Integration

The ERG protocol integrates from early discovery through preclinical validation, supporting hypothesis testing, mechanistic de-risking, and quantitative assessment of neuroprotective interventions.

• Discovery Biology: Provides functional readouts for hypothesis-driven evaluation of retinal protection mechanisms.
• Screening: Delivers reproducible, quantitative ERG outputs for compound and intervention screening.
• Analytics: Enables measurement of A wave and B wave amplitudes and latencies for comparative analysis.
• Translational Research: Bridges discovery and preclinical phases with disease-relevant functional endpoints.
• Enterprise Reuse: Offers a standardized, minimally invasive platform adaptable to diverse retinal injury and neuroprotection studies.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in neuroprotection studies.
• Operational Value: Standardizes functional assessment, ensuring reproducibility and scalability across studies.
• Strategic Value: Informs go/no-go decisions and enhances capital efficiency by providing robust functional endpoints.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of neuroprotective candidates.

Implementation Considerations

• Requires expertise in electrophysiology and rodent handling for reliable ERG acquisition.
• Needs calibrated light stimulus delivery and precise electrode placement for reproducible results.
• Demands cross-team standardization of anesthesia, adaptation, and recording parameters.
• Adaptable to various retinal injury models and neuroprotective intervention studies.
• Limited sensitivity for detecting localized retinal damage; best suited for pan-retinal functional assessment.

Biopharma FAQs